8-K: Synergy CHC Secures $20 Million Long-Term Credit Facility to Refinance Debt and Fuel Growth

Synergy CHC Corp. has announced a new $20 million term loan credit agreement with ACP Agency, LLC, aimed at refinancing existing debt and providing capital for strategic growth initiatives.

Summary

• Synergy CHC Corp. entered into a Term Loan Credit Agreement with ACP Agency, LLC on May 30, 2025, for a total facility of $20.0 million.
• The facility includes a $15.0 million term loan received at closing, a committed delayed draw facility of up to $2.5 million, and an uncommitted incremental facility of up to $2.5 million.
• Proceeds from the initial term loan will be used to repay existing indebtedness, cover transaction costs, and provide working capital.
• The delayed draw facility proceeds are specifically earmarked to pay off outstanding obligations under the Atrium Settlement Agreement and the Vitabest Settlement Agreement.
• The term loan bears interest at the Term SOFR rate plus 8.50%, with interest-only payments through 2025.
• Quarterly principal payments of $175,000 will commence in January 2026, increasing to $350,000 per quarter from January 2027 onwards.
• The stated maturity date for the term loan is May 30, 2029.
• The credit facility is secured by all assets of the Company and certain subsidiaries, including intellectual property and equity interests.
• The agreement includes customary representations, warranties, and covenants, such as restrictions on indebtedness, liens, restricted payments, and asset sales.
• Mandatory prepayments are required from excess cash flow (ranging from 0% to 50% based on Consolidated Senior Net Leverage Ratio), certain dispositions, other indebtedness incurrences, extraordinary receipts, and equity issuances.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the new credit facility provides crucial liquidity, refinances existing debt, and offers growth capital, the high interest rate and strict financial covenants indicate a higher risk profile and potential operational constraints. The resolution of settlement agreements is a clear positive, but the overall terms suggest a company navigating a challenging financial landscape.

Positives

• The new $20 million long-term credit facility provides significant liquidity and strengthens the Company's capital structure.
• The refinancing allows for the repayment of existing indebtedness, reducing immediate financial burdens.
• The delayed draw facility specifically addresses and allows for the full repayment of obligations under the Atrium and Vitabest settlement agreements, resolving past legal liabilities.
• The facility provides working capital and growth capital, offering flexibility for future strategic initiatives and business expansion.
• The interest-only period through 2025 provides immediate cash flow relief, allowing the company to stabilize before principal repayments begin.

Negatives

• The interest rate of Term SOFR plus 8.50% is relatively high, indicating a higher cost of capital for the Company.
• The credit agreement imposes strict financial covenants, including a decreasing maximum Consolidated Senior Net Leverage Ratio (from 3.25:1.00 to 2.50:1.00 by December 31, 2026) and a minimum Fixed Charge Coverage Ratio of 1.20, which could limit operational flexibility.
• The loan is secured by substantially all assets of the Company and its subsidiaries, including intellectual property, which represents a significant encumbrance.
• Prepayment penalties (Applicable Premium) are substantial, especially in the first year (3.0% of outstanding principal or foregone interest), potentially disincentivizing early repayment.
• The requirement for Jack Ross to pledge additional shares if the Boombod Promissory Note is not paid by January 1, 2026, introduces a potential future equity pledge by a key executive.

Risks

• Failure to comply with the Consolidated Senior Net Leverage Ratio or Fixed Charge Coverage Ratio covenants could trigger an Event of Default, leading to acceleration of the loan.
• The Company faces mandatory prepayments from various sources, including excess cash flow, dispositions, and equity issuances, which could limit retained earnings and reinvestment opportunities.
• Failure to satisfy conditions subsequent, such as delivering landlord waivers, control agreements, or obtaining consent from Knight Therapeutics International S.A., could result in an Event of Default.
• The Pledged Promissory Note from Boombod Ltd. not being paid by January 1, 2026, could lead to Jack Ross pledging additional shares, potentially impacting his ownership stake and control.
• The high interest rate increases the Company's debt servicing costs, which could strain profitability, especially if revenues do not grow as anticipated.

Future Outlook

The Company anticipates that the long-term nature of the new credit facility will enhance its balance sheet and provide the necessary flexibility for its next phase of growth. The ability to fully repay debt related to settlement agreements is expected to position the Company for greater financial stability as it executes its strategic goals.

Management Comments

• "We are very pleased to have completed our debt refinancing, which supports our growth strategy and significantly strengthens our capital structure."
• "The long-term nature of the new facility enhances our balance sheet and provides the flexibility needed for our next phase of growth."
• "Additionally, the delayed draw proceeds allow us to fully repay debt related to settlement agreements, positioning us for greater financial stability as we execute our strategic goals."

Industry Context

This financing move by Synergy CHC Corp., a provider of consumer health care and lifestyle products, reflects a common strategy in the consumer goods sector to optimize capital structure for growth. Companies in this industry often seek flexible financing to support product development, marketing, and potential acquisitions, especially in competitive markets like brain health supplements (FOCUSfactor) and weight management (Flat Tummy). The long-term nature of the facility suggests a focus on sustained growth rather than short-term liquidity fixes, aligning with broader industry trends of strategic investment in brand portfolios.

Comparison to Industry Standards

• The interest rate of SOFR + 8.50% is on the higher end for corporate debt, suggesting a higher perceived risk by the lender compared to larger, more established consumer health companies like Procter & Gamble (PG) or Johnson & Johnson (JNJ) which typically secure financing at much lower rates due to their strong credit ratings and diversified revenue streams.
• The leverage covenants, starting at 3.25:1.00 and stepping down to 2.50:1.00, are relatively tight for a growth-oriented company, indicating a lender's focus on rapid de-leveraging. For comparison, some private equity-backed consumer companies might operate with initial leverage ratios of 4x-6x EBITDA, though often with different debt structures.
• The Fixed Charge Coverage Ratio of 1.20 is a standard, but somewhat tight, requirement, meaning the company must maintain a relatively thin margin of earnings over its fixed obligations. This is comparable to benchmarks seen in middle-market lending for companies with moderate cash flow stability.
• The extensive collateral package, including all assets and intellectual property, is typical for asset-backed loans to smaller or mid-sized companies in the consumer sector, reflecting the importance of brand value and inventory in securing such facilities.
• The prepayment penalties are customary for term loans of this nature, designed to compensate lenders for lost interest income, but the tiered structure is a common feature to incentivize earlier repayment over time.

Legal Proceedings

• The proceeds from the Delayed Draw Facility will be used to pay off all indebtedness owed by the Company pursuant to the Atrium Settlement Agreement (effective December 28, 2023) and the Vitabest Settlement Agreement (effective March 27, 2024), indicating resolution of prior legal disputes.

Related Party Transactions

• The Sanders Notes, consisting of $6,000,000 in Senior Subordinated Debentures and a $2,000,000 promissory note, were issued to certain clients of Don A. Sanders and Don A. Sanders, respectively. Payments on these notes are subject to specific financial conditions and subordination agreements.

Stakeholder Impact

• **Shareholders**: The refinancing provides financial stability and growth capital, potentially increasing shareholder value by reducing debt and enabling strategic initiatives. However, the high cost of debt and strict covenants could impact future profitability and flexibility.
• **Creditors (ACP Agency, LLC)**: ACP Agency, LLC benefits from a secured, high-interest loan with extensive collateral and strict covenants, providing strong protection for their investment.
• **Creditors (Existing)**: Existing indebtedness will be repaid, providing a positive outcome for prior lenders.
• **Creditors (Sanders Notes holders)**: Payments on Sanders Notes are subordinated and subject to specific financial conditions, indicating a lower priority in the capital structure compared to the new term loan.
• **Employees**: Improved financial stability could lead to a more secure work environment and potential for growth opportunities.
• **Customers**: Enhanced financial health may allow for continued investment in product development and marketing for brands like FOCUSfactor and Flat Tummy, potentially benefiting customers through improved offerings.

Next Steps

• The Company will begin quarterly principal payments of $175,000 on the Term Loan in January 2026, increasing to $350,000 in January 2027.
• The Company must comply with various conditions subsequent within specified timeframes (e.g., 10-30 business days post-Effective Date) including delivering pledged interests, insurance evidence, landlord waivers, control agreements, and obtaining consent from Knight Therapeutics International S.A.
• The Company must maintain compliance with financial covenants, including the Consolidated Senior Net Leverage Ratio and Fixed Charge Coverage Ratio, with targets becoming stricter over time.
• The Pledged Promissory Note from Boombod Ltd. must be paid in full by January 1, 2026, or Jack Ross will be required to pledge shares of the Borrower's stock as security.
• The Company will continue to provide monthly, quarterly, and annual financial statements and compliance certificates to the Agents and Lenders.

Key Dates

Recommendation

Keywords

Synergy CHC Corp., SNYR, Term Loan, Credit Facility, Debt Refinancing, Capital Structure, SEC Filing, 8-K, Financial Covenants, SOFR, Leverage Ratio, Fixed Charge Coverage, Prepayment Penalty, Settlement Agreements, Corporate Finance, Consumer Health Care, Lifestyle Products